BioScrip On Track To Return To Profitability

ELMSFORD, N.Y.--(BUSINESS WIRE)--BioScrip, Inc. (NASDAQ:BIOS), a comprehensive pharmaceutical care solutions company, today announced that the Company is continuing to make strides towards returning to profitability, primarily through improving collections, reducing expenses, and enhancing top line growth. During the third quarter, the Company refocused its billing and collections efforts and implemented new operational procedures to ensure better collections at the point of sale. These initiatives enabled BioScrip to lower bad debt expense by $1.6 million from the prior quarter, which should positively impact fourth quarter results.